{"brief_title": "Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1", "brief_summary": "The purpose of this study is to assess the clinical efficacy of the buprenorphine/naloxone combination tablet for alternate-day dosing and determine whether multiples of the daily dose are necessary to maintain an effective alternate day dosing regimen.", "detailed_description": "Alternate-day dosing with the 8mg buprenorphine-naloxone tablet is as safe and effective as daily dosing. Outcomes are improved when the total weekly dose provided during alternate-day dosing is equal to that given during daily dosing.", "condition": "Opioid-Related Disorders", "intervention_type": "Drug", "intervention_name": "Heroin Dependence", "criteria": "Inclusion Criteria: Individuals must be currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency. Exclusion Criteria: Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "64 Years", "healthy_volunteers": "No", "id": "NCT00000326.xml"}